Lv11
70 积分 2023-11-29 加入
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
2小时前
待确认
Gut-directed therapeutics in inflammatory bowel disease
3个月前
已完结
Potent and Selective RIPK1 Inhibitors Targeting Dual‐Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis
3个月前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
5个月前
已完结
Ozanimod for Ulcerative Colitis
5个月前
已完结
Ulcerative Colitis in Adults
5个月前
已完结
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
5个月前
已完结
Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development
6个月前
已完结
Development of a novel bispecific antibody GR1801 for rabies
6个月前
已完结
Etrasimod for the treatment of ulcerative colitis
7个月前
已完结
皖公网安备34019202002308
